$0.00
(Market cap
$8 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
1.2
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-2.4 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-0.1
-
Debt to Equity
0
-
Book Value
$0.3
-
EPS
$-1.3
-
Face value
--
-
Shares outstanding
21,765,479
10 Years Aggregate
CFO
$-78.55 Mln
EBITDA
$-99.57 Mln
Net Profit
$-93.36 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Soligenix (SNGX)
| -71.9 | 4.1 | -56.5 | -87.4 | -63.1 | -72.6 | -56.4 |
|
BSE Sensex
| -8.8 | 0.6 | 1.8 | -4.4 | 6.0 | 6.6 | 10.8 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Soligenix (SNGX)
| -50.3 | -77.6 | -88.8 | -31.8 | -48.4 | -11.7 | 68.6 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Soligenix (SNGX)
|
0.4 | 8.2 | 0.0 | -10.2 | -- | -171.5 | -- | 1.2 |
| 84.9 | 11,993.9 | 669.5 | -320.0 | -0.8 | -71.1 | -- | 26.9 | |
| 247.9 | 16,261.1 | 1,054.4 | 755.9 | 5.7 | -- | 19 | 9.8 | |
| 72.1 | 10,022.2 | 71.0 | -894.0 | -1,175.8 | -- | -- | 60.3 | |
| 54.5 | 13,491.7 | 2,435.9 | 860.6 | 31.0 | 43 | 17.4 | 7.4 | |
| 105.4 | 11,957.0 | 1,663.7 | 413.6 | 36.3 | 430 | 30.9 | 84.5 | |
| 351.5 | 10,402.8 | 440.5 | 241.5 | 33.4 | 18.7 | 44.1 | 7.8 | |
| 533.8 | 12,332.1 | 1,283.9 | -325.1 | -19.0 | -57.7 | -- | 24.0 | |
| 600.7 | 16,765.1 | 2,782.3 | 491.5 | 21.1 | 110.1 | 35.2 | 39.3 | |
| 344.8 | 9,625.4 | 0.0 | -339.1 | -- | -30.6 | -- | 7.6 |
Shareholding Pattern
View DetailsAbout Soligenix (SNGX)
Soligenix, Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public... Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a photodynamic therapy, which has completed Phase 3 clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator (IDR) technology that is in Phase 3 clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer; SGX945, an IDR technology that is in Phase 2a study to treat aphthous ulcers in Behçet's disease; and SGX302, an IDR technology, which is in Phase 2a study for the treatment of mild-to-moderate psoriasis. Its Public Health Solutions segment engages in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase 1a, 1b, and 1c clinical trials; SGX943, a therapeutic candidate in preclinical studies for the treatment of antibiotic-resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; CiVax, a vaccine candidate for the prevention of COVID-19; and vaccine programs that target filoviruses, such as Marburg and Ebola. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in September 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey. Read more
-
Chairman of the Board of Directors, CEO & President
Dr. Christopher J. Schaber Ph.D.
-
Chairman of the Board of Directors, CEO & President
Dr. Christopher J. Schaber Ph.D.
-
Headquarters
Princeton, NJ
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Soligenix (SNGX)
What is the current share price of Soligenix Inc (SNGX) Today?
The share price of Soligenix Inc (SNGX) is $0.38 (NASDAQ) as of 28-Aug-2026 16:00 EDT. Soligenix Inc (SNGX) has given a return of -63.13% in the last 3 years.
What is the current PB & PE ratio of Soligenix Inc (SNGX)?
Since, TTM earnings of Soligenix Inc (SNGX) is negative, P/E ratio is not available.
The P/B ratio of Soligenix Inc (SNGX) is 1.23 times as on 28-Aug-2026, a 76 discount to its peers’ median range of 5.18 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-1.22 |
2.55 |
2024 |
-0.82 |
1.65 |
2023 |
-0.08 |
0.20 |
2022 |
-0.01 |
-0.03 |
2021 |
-0.01 |
0.01 |
What is the 52 Week High and Low of Soligenix Inc (SNGX)?
The 52-week high and low of Soligenix Inc (SNGX) are Rs 3.22 and Rs 0.28 as of 31-Aug-2026.
What is the market cap of Soligenix Inc (SNGX)?
Soligenix Inc (SNGX) has a market capitalisation of $ 8 Mln as on 28-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Soligenix Inc (SNGX)?
Before investing in Soligenix Inc (SNGX), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.